Welcome to our dedicated page for DermTech news (Ticker: DMTK), a resource for investors and traders seeking the latest updates and insights on DermTech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DermTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DermTech's position in the market.
Summary not available.
Summary not available.
DermTech, Inc. (NASDAQ: DMTK) will host a conference call and webcast on May 4, 2023, at 5:00 p.m. ET to discuss its first-quarter 2023 operating and financial results. An earnings press release will be issued prior to the call. Interested participants can register for Q&A or listen via webcast. DermTech focuses on precision dermatology through a non-invasive skin genomics platform, aiming to enhance individualized care. The company is dedicated to early skin cancer detection and developing solutions for inflammatory diseases. For more details, visit DermTech's website.
Forward-looking statements are included, emphasizing potential future risks and uncertainties affecting performance and market opportunities.
DermTech (NASDAQ: DMTK) has announced a contract with a major Blues plan in North Carolina, enhancing access to its DermTech Melanoma Test (DMT) for over 3.8 million members. This agreement builds on a favorable coverage policy that began on March 15, 2023, allowing the test to be available as an in-network benefit.
The DMT offers a non-invasive method for enhanced melanoma detection, boasting a negative predictive value exceeding 99%. With this contract, DermTech aims to improve patient care and reduce healthcare costs, recognizing the value of its clinical and economic data among payers. Overall, DermTech has around 126 million covered lives in the U.S., including 68 million for Medicare and 58 million for commercial payers.
Summary not available.
DermTech (NASDAQ: DMTK) is participating in the 2023 American Academy of Dermatology Annual Meeting from March 17-21 in New Orleans. The company will present four new posters related to basal cell carcinoma diagnostics and melanoma detection. Key presentations include non-invasive RNA detection and performance of the pigmented lesion assay on higher Fitzpatrick Skin Types. DermTech will showcase its innovative melanoma test, which boasts a negative predictive value over 99%, at booth #2839. The company also commits to donating $100 to AAD Skin Cancer Awareness for each badge scanned during the event. DermTech aims to enhance awareness and access to melanoma screening solutions.
DermTech has forged a significant agreement with a Blues plan in Arizona, granting access to the DermTech Melanoma Test (DMT) for approximately 1.9 million members. This innovative, non-invasive assay enhances melanoma detection, boasting a greater than 99% negative predictive value (NPV). With this deal, DermTech’s total covered lives in the U.S. climbs to around 126 million, including 68 million for Medicare and 58 million for commercial payers. The company is dedicated to precision dermatology, focusing on improving patient outcomes while aiming to reduce healthcare costs.
DermTech (NASDAQ: DMTK), a leader in precision dermatology, announced its participation in two investor conferences in March 2023. The company will present at the TD Cowen 43rd Annual Health Care Conference in Boston on March 8 at 1:30 p.m. ET and the Oppenheimer 33rd Annual Healthcare Conference virtually on March 14 at 10:00 a.m. ET. Live webcasts will be available on DermTech's investor relations website, with replays accessible for 90 days. DermTech focuses on providing non-invasive precision dermatology solutions for early skin cancer detection and tailored treatment for inflammatory diseases.